$4.25
0.0%
Downside
Day's Volatility :6.8%
Upside
6.8%
6.59%
Downside
52 Weeks Volatility :44.32%
Upside
40.4%
Period | Champions Oncology Inc | Index (Russel 2000) |
---|---|---|
3 Months | -7.61% | 0.0% |
6 Months | -24.24% | 0.0% |
1 Year | -32.65% | 0.0% |
3 Years | -57.5% | -22.3% |
Market Capitalization | 62.0M |
Book Value | - $0.14 |
Earnings Per Share (EPS) | -0.54 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.0 |
Profit Margin | -14.51% |
Operating Margin TTM | 1.17% |
Return On Assets TTM | -14.31% |
Return On Equity TTM | -532.46% |
Revenue TTM | 50.2M |
Revenue Per Share TTM | 3.7 |
Quarterly Revenue Growth YOY | 7.1% |
Gross Profit TTM | 24.3M |
EBITDA | -5.1M |
Diluted Eps TTM | -0.54 |
Quarterly Earnings Growth YOY | -0.29 |
EPS Estimate Current Year | -0.63 |
EPS Estimate Next Year | -0.34 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 41.18%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 27.1M | ↑ 33.72% |
Net Income | 128.0K | ↓ 108.5% |
Net Profit Margin | 0.47% | ↑ 7.91% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 32.1M | ↑ 18.68% |
Net Income | -2.0M | ↓ 1642.97% |
Net Profit Margin | -6.15% | ↓ 6.62% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 41.0M | ↑ 27.76% |
Net Income | 362.0K | ↓ 118.33% |
Net Profit Margin | 0.88% | ↑ 7.03% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 49.1M | ↑ 19.66% |
Net Income | 548.0K | ↑ 51.38% |
Net Profit Margin | 1.12% | ↑ 0.24% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 53.9M | ↑ 9.69% |
Net Income | -5.3M | ↓ 1073.54% |
Net Profit Margin | -9.9% | ↓ 11.02% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 50.2M | ↓ 6.9% |
Net Income | -7.3M | ↑ 36.38% |
Net Profit Margin | -14.51% | ↓ 4.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.8M | ↓ 10.56% |
Net Income | -2.4M | ↑ 15143.75% |
Net Profit Margin | -19.09% | ↓ 18.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.1M | ↑ 2.33% |
Net Income | -2.6M | ↑ 5.0% |
Net Profit Margin | -19.59% | ↓ 0.5% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.6M | ↓ 3.9% |
Net Income | -2.6M | ↑ 0.2% |
Net Profit Margin | -20.43% | ↓ 0.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.6M | ↓ 7.87% |
Net Income | -2.1M | ↓ 19.29% |
Net Profit Margin | -17.9% | ↑ 2.53% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 12.0M | ↑ 3.85% |
Net Income | -2.5M | ↑ 22.16% |
Net Profit Margin | -21.05% | ↓ 3.15% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 14.0M | ↑ 16.49% |
Net Income | -109.0K | ↓ 95.69% |
Net Profit Margin | -0.78% | ↑ 20.27% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.3M | ↑ 39.45% |
Total Liabilities | 9.0M | ↑ 11.4% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 20.8M | ↑ 84.21% |
Total Liabilities | 15.4M | ↑ 70.96% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 27.6M | ↑ 32.96% |
Total Liabilities | 20.2M | ↑ 30.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 35.4M | ↑ 28.22% |
Total Liabilities | 26.3M | ↑ 30.35% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 34.3M | ↓ 3.02% |
Total Liabilities | 29.7M | ↑ 12.91% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 26.1M | ↓ 23.84% |
Total Liabilities | 28.0M | ↓ 5.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 36.2M | ↓ 0.59% |
Total Liabilities | 29.1M | ↑ 6.97% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 34.3M | ↓ 5.09% |
Total Liabilities | 29.7M | ↑ 2.02% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 29.9M | ↓ 12.84% |
Total Liabilities | 28.0M | ↓ 5.63% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 28.3M | ↓ 5.39% |
Total Liabilities | 28.2M | ↑ 0.71% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 26.8M | ↓ 5.33% |
Total Liabilities | 28.8M | ↑ 2.28% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 26.1M | ↓ 2.45% |
Total Liabilities | 28.0M | ↓ 2.81% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.9M | ↓ 251.88% |
Investing Cash Flow | -834.0K | ↓ 31.97% |
Financing Cash Flow | 1.2M | ↑ 9153.85% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.9M | ↑ 56.02% |
Investing Cash Flow | -2.2M | ↑ 166.19% |
Financing Cash Flow | 4.4M | ↑ 267.41% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.7M | ↓ 157.87% |
Investing Cash Flow | -3.2M | ↑ 42.75% |
Financing Cash Flow | 1.2M | ↓ 72.96% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.5M | ↓ 486.5% |
Investing Cash Flow | -2.4M | ↓ 24.77% |
Financing Cash Flow | 207.0K | ↓ 82.68% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.0M | ↓ 39.13% |
Investing Cash Flow | -2.9M | ↑ 20.47% |
Financing Cash Flow | 11.0K | ↓ 94.69% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.6M | ↓ 52.13% |
Investing Cash Flow | -754.0K | ↑ 24.83% |
Financing Cash Flow | -75.0K | ↓ 187.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -709.0K | ↓ 145.07% |
Investing Cash Flow | -760.0K | ↑ 0.8% |
Financing Cash Flow | -75.0K | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.0M | ↑ 462.91% |
Investing Cash Flow | -668.0K | ↓ 12.11% |
Financing Cash Flow | -590.0K | ↑ 686.67% |
Sell
Neutral
Buy
Champions Oncology Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Champions Oncology Inc | -5.56% | -24.24% | -32.65% | -57.5% | -29.17% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Champions Oncology Inc | NA | NA | 0.0 | -0.63 | -5.32 | -0.14 | NA | -0.14 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Champions Oncology Inc | Sell | $62.0M | -29.17% | NA | -14.51% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Champions Oncology Inc
Revenue is up for the last 3 quarters, 11.57M → 14.00M (in $), with an average increase of 8.9% per quarter
Netprofit is up for the last 2 quarters, -2.53M → -109.0K (in $), with an average increase of 2221.1% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 69.7%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 126.7%
Battery Management Corp
NEA Management Company, LLC
Tocqueville Asset Management L.P.
Renaissance Technologies Corp
BlackRock Inc
Vanguard Group Inc
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Organization | Champions Oncology Inc |
Employees | 210 |
CEO | Dr. Ronnie Morris M.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$4.25
+0.0%
Keyarch Acquisition Corp
$4.25
+0.0%
Connexa Sports Technologies Inc
$4.25
+0.0%
Us Value Etf
$4.25
+0.0%
First Wave Biopharma Inc
$4.25
+0.0%
Global X Msci Next Emerging
$4.25
+0.0%
Fat Projects Acquisition Corp
$4.25
+0.0%
Capital Link Global Fintech
$4.25
+0.0%
Applied Uv Inc
$4.25
+0.0%